As investment interest in hair loss treatment development companies continues to grow globally, South Korean pharmaceutical firm Samik Pharmaceutical is experiencing strong early trading gains.
According to the Korea Exchange, as of 10:15 a.m. on September 15, Samik Pharmaceutical's shares rose by 1,580 won (17.04%) to 10,850 won. During the session, the stock peaked at 12,050 won, up 2,780 won (29.99%) from the previous trading day, before giving back some gains.
The surge in Samik Pharmaceutical's stock is attributed to the recent announcement that the company has completed the registration of a domestic patent for its long-acting formulation technology of the immune-regulating peptide Thymosin alpha 1. This technology involves encapsulating Thymosin alpha 1 in biodegradable polymer microspheres, allowing for gradual drug release in the body. Unlike traditional oral medications taken daily, this treatment requires an injection once a month.
Notably, the recent excitement in the U.S. stock market surrounding hair loss treatment developers has led to a reevaluation of companies with related technologies. Bloomberg reported on August 29 that hair loss treatment developers are becoming a new focus for investment on Wall Street, following interest in obesity treatments. For instance, shares of U.S. company Veradermix have surged nearly 500% since its listing in February, reflecting a broader trend of rising stock prices in this sector.
Additionally, other companies such as JW Pharmaceutical (up 7.7%), Myungmoon Pharmaceutical (up 5.42%), and Hyundai Pharmaceutical (up 1.4%) are also seeing gains.
According to the Korea Exchange, as of 10:15 a.m. on September 15, Samik Pharmaceutical's shares rose by 1,580 won (17.04%) to 10,850 won. During the session, the stock peaked at 12,050 won, up 2,780 won (29.99%) from the previous trading day, before giving back some gains.
The surge in Samik Pharmaceutical's stock is attributed to the recent announcement that the company has completed the registration of a domestic patent for its long-acting formulation technology of the immune-regulating peptide Thymosin alpha 1. This technology involves encapsulating Thymosin alpha 1 in biodegradable polymer microspheres, allowing for gradual drug release in the body. Unlike traditional oral medications taken daily, this treatment requires an injection once a month.
Notably, the recent excitement in the U.S. stock market surrounding hair loss treatment developers has led to a reevaluation of companies with related technologies. Bloomberg reported on August 29 that hair loss treatment developers are becoming a new focus for investment on Wall Street, following interest in obesity treatments. For instance, shares of U.S. company Veradermix have surged nearly 500% since its listing in February, reflecting a broader trend of rising stock prices in this sector.
Additionally, other companies such as JW Pharmaceutical (up 7.7%), Myungmoon Pharmaceutical (up 5.42%), and Hyundai Pharmaceutical (up 1.4%) are also seeing gains.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.